Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O
Department of Urology, Helsinki University Central Hospital, Finland.
J Urol. 1995 Dec;154(6):2050-3.
Our aim was to prove if alternating chemotherapeutic and immunotherapeutic instillations improved efficacy and reduced toxicity in patients with carcinoma in situ of the bladder.
Of 68 carcinoma in situ patients randomly treated with instillations 40 received mitomycin C and 28 received mitomycin C and Pasteur bacillus Calmette-Guerin (BCG) in alternating courses. Mean followup was 33 months.
The complete response rates with mitomycin C and mitomycin C/BCG were 45% and 71% at 3 months, 59% and 82% at 12 months, and 47% and 74% at 24 months, respectively (p = 0.041). The disease-free interval showed the superiority of alternating therapy (p = 0.043). Recurrence rates during the instillation period were 1.834 with mitomycin C and 0.922 with mitomycin C/BCG (p = 0.013). No remarkable side effects developed in the alternating group.
Therapy of carcinoma in situ with alternating mitomycin C and BCG is more effective than mitomycin C alone. Compared to BCG monotherapy only few side effects occur.
我们的目的是证明交替进行化疗和免疫治疗灌注是否能提高膀胱原位癌患者的疗效并降低毒性。
68例原位癌患者随机接受灌注治疗，40例接受丝裂霉素C，28例接受丝裂霉素C和卡介苗（BCG）交替疗程治疗。平均随访33个月。
丝裂霉素C组和丝裂霉素C/BCG组在3个月时的完全缓解率分别为45%和71%，12个月时分别为59%和82%，24个月时分别为47%和74%（p = 0.041）。无病生存期显示交替治疗具有优势（p = 0.043）。灌注期间丝裂霉素C组的复发率为1.834，丝裂霉素C/BCG组为0.922（p = 0.013）。交替治疗组未出现明显副作用。
丝裂霉素C和卡介苗交替治疗膀胱原位癌比单独使用丝裂霉素C更有效。与卡介苗单一疗法相比，副作用较少。
